Basit öğe kaydını göster

dc.contributor.authorDayangac-Erden, Didem
dc.contributor.authorBora-Tatar, Gamze
dc.contributor.authorDalkara, Sevim
dc.contributor.authorDemir, Ayhan S.
dc.contributor.authorErdem-Yurter, Hayat
dc.date.accessioned2019-12-12T06:27:06Z
dc.date.available2019-12-12T06:27:06Z
dc.date.issued2011
dc.identifier.issn1734-1922
dc.identifier.urihttps://doi.org/10.5114/aoms.2011.22072
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258711/
dc.identifier.urihttp://hdl.handle.net/11655/16439
dc.description.abstractIntroduction Proximal spinal muscular atrophy (SMA) is a common autosomal recessively inherited neuromuscular disorder. It is caused by homozygous absence of the survival motor neuron 1 (SMN1) gene. SMN2, which modulates the severity of the disease, represents a major target for therapy. The aim of this study was to investigate whether SMN2 expression can be increased by caffeic acid, chlorogenic acid and curcumin, which are designed by modifications of the carboxylic acid class of histone deacetylase (HDAC) inhibitors. Material and methods Using quantitative real-time PCR, we analysed the levels of full-length SMN2 and Δ7SMN2 mRNA. We performed LDH cytotoxicity assay to analyse whether SMN2 activating concentrations of caffeic acid, chlorogenic acid and curcumin were cytotoxic to fibroblasts. Results We found that caffeic acid and curcumin were more efficient than chlorogenic acid and increased full-length SMN2 mRNA levels 1.5 and 1.7-fold, respectively. Δ7SMN2 mRNA levels were measured to investigate alternative splicing of exon 7. We also found that cytotoxicity was not observed at SMN2 activating concentrations. Conclusions Our data suggest that carboxylic acid derivatives including phenolic structure and symmetry could be a good candidate for SMA treatment.
dc.language.isoen
dc.relation.isversionof10.5114/aoms.2011.22072
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleCarboxylic Acid Derivatives of Histone Deacetylase Inhibitors Induce Full Length Smn2 Transcripts: A Promising Target For Spinal Muscular Atrophy Therapeutics
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalArchives of Medical Science : AMS
dc.contributor.departmentTıbbi Biyoloji
dc.identifier.volume7
dc.identifier.issue2
dc.identifier.startpage230
dc.identifier.endpage234
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster